Further Analyses To Delay Ipsen’s Palovarotene Progress In Ultra-Rare Disease
Withdraws US Marketing Submission
Executive Summary
Ipsen has withdrawn the US NDA for palovarotene in an ultra-rare bone condition in order to conduct additional data analyses, but intends to resubmit once they are complete.
You may also be interested in...
Ipsen To Exit Consumer Health And Focus On Specialty Pharma
The French group is sharpening its focus on specialty care in oncology, rare disease and neuroscience, so is looking to divest its consumer health division to Mayoly Spindler.
Ipsen Gives Genfit Liver Drug New Lease Of Life
The French biotech was firmly on the ropes last year after elafibranor joined the long list of failures for NASH but the promise it has shown in primary biliary cholangitis has persuaded Ipsen to part with a hefty upfront fee.
Keeping Track: Merck & Co. In Spotlight With Welireg, Keytruda Approvals; FibroGen/AZ Roxadustat CRL Is No Surprise
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.